(Reuters) -Peter Marks, the FDA's top vaccine official ousted by Robert F. Kennedy Jr. said the U.S. health secretary's team ...

The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, ...

Dr. Peter Marks is being forced to resign from the FDA because the Trump administration does not want someone who is ...

Bullish option flow detected in Novavax (NVAX) with 12,673 calls trading, 2x expected, and implied vol increasing almost 14 points to 90.76%.

US biotech Novavax (Nasdaq: NVAX) is still waiting on a decision from the Food and Drug Administration over full approval of its protein-based COVID-19 vaccine, despite the agency having set an April ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putting future approvals in jeopardy, according to multiple reports.

While it’s not unusual for certain positions to turn over with a new administration, the number of senior-level FDA staffers ...

Trump previously floated a 25% tariff on all imported drugs, though they were unaffected by recent reciprocal levies.

President Donald Trump's administration has decided not to cover expensive, high-demand obesity treatments under the ...

"Just where is that extensive 5000 word longform apology from Adam Cifu over at Sensible Medicine, begging forgiveness for ...

Generating significant returns and multiplying their money in the stock market remains a primary goal for most investors.